-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DowuQx43FuOLLczdRgmGwLo5k0D1u5u0pROQ45xgXFP80V2CKdoFxjHrCpW9auwI
 jCc6FRsfQgKz8RZ47PtSmQ==

<SEC-DOCUMENT>0000950116-04-003877.txt : 20041222
<SEC-HEADER>0000950116-04-003877.hdr.sgml : 20041222
<ACCEPTANCE-DATETIME>20041222141304
ACCESSION NUMBER:		0000950116-04-003877
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041222
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041222
DATE AS OF CHANGE:		20041222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMPAX LABORATORIES INC
		CENTRAL INDEX KEY:			0001003642
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				650403311
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27354
		FILM NUMBER:		041220220

	BUSINESS ADDRESS:	
		STREET 1:		30831 HAYWARD AVE
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94544
		BUSINESS PHONE:		2152892220

	MAIL ADDRESS:	
		STREET 1:		CASTOR & KENSINGTON AVENUES
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19124-5694

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL PHARMACEUTICAL CORP \DE\
		DATE OF NAME CHANGE:	19951117
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eight-k.txt
<DESCRIPTION>EIGHT-K.TXT
<TEXT>
<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                    FORM 8-K


                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


     Date of report (Date of earliest event reported):        December 22, 2004

                            Impax Laboratories, Inc.
- --------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)


<TABLE>
<CAPTION>

<S>                                                <C>                                           <C>
          Delaware                                 0-27354                                       65-0403311
- ----------------------------------------------------------------------------------------------------------------------
(State or other jurisdiction                (Commission File Number)                 (IRS Employer Identification No.)
     of incorporation)

             30831 Huntwood Ave., Hayward, CA                                                    94544
- ----------------------------------------------------------------------------------------------------------------------
         (Address of principal executive offices)                                             (Zip Code)
</TABLE>

        Registrant's telephone number, including area code (510) 476-2000

                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


ITEM 7.01. REGULATION FD DISCLOSURE

         On December 22, 2004, Impax Laboratories, Inc. (the "Company") issued a
press release announcing that the Company has begun commercial distribution of
its Bupropion Hydrochloride 200 mg Extended Release Tablets. A copy of the press
release is attached as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS

                  (c)  Exhibits.

                           99.1 - Press release dated December 22, 2004.



                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                       IMPAX LABORATORIES, INC.


Date:   December 22, 2004              By: /s/    Cornel C. Spiegler
                                           -------------------------------------
                                           Name:  Cornel C. Spiegler
                                           Title: Chief Financial Officer





</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.txt
<DESCRIPTION>EX99-1.TXT
<TEXT>
<PAGE>

[GRAPHIC OMITTED]


COMPANY CONTACTS:                     INVESTOR RELATIONS CONTACTS:
IMPAX Laboratories, Inc.              Lippert/Heilshorn & Associates, Inc.
Barry R. Edwards, CEO                  Kim Sutton Golodetz (kgolodetz@lhai.com)
(215) 933-0323 Ext. 4360              (212) 838-3777
Larry Hsu, Ph.D., President           Bruce Voss (bvoss@lhai.com)
(510) 476-2000 Ext. 1111              (310) 691-7100
Cornel C. Spiegler, CFO               www.lhai.com
(215) 289-2220 Ext. 1706
www.impaxlabs.com



         IMPAX LAUNCHES GENERIC VERSION OF WELLBUTRIN SR 200 MG TABLETS

HAYWARD, CALIF. (DECEMBER 22, 2004) - IMPAX LABORATORIES, INC. (NASDAQ NM: IPXL)
today announced that the Company has begun commercial distribution of its
Bupropion Hydrochloride 200 mg Extended Release Tablets. The product is being
sold under the Global label and marketed by IMPAX's Global Pharmaceuticals
division.

As previously announced, the U.S. Food and Drug Administration (FDA) granted
final approval to the Company's Abbreviated New Drug Application for a generic
version of Wellbutrin SR(R) (Bupropion Hydrochloride) 200mg Tablets on December
3, 2004. The FDA also awarded the Company first-to-file status and 180-day
market exclusivity for this product. GlaxoSmithKline markets Wellbutrin SR for
the treatment of depression. U.S. sales of Wellbutrin SR 200mg Tablets were
approximately $212 million in the 12 months ended October 31, 2004, according to
NDCHealth.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company
applying its formulation expertise and drug delivery technology to the
development of controlled-release and specialty generics in addition to the
development of branded products. IMPAX markets its generic products through its
Global Pharmaceuticals division and intends to market its branded products
through the IMPAX Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully leverage its
technology platform. IMPAX Laboratories is headquartered in Hayward, California,
and has a full range of capabilities in its Hayward and Philadelphia facilities.
For more information, please visit the Company's Web site at: www.impaxlabs.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
To the extent any statements made in this news release contain information that
is not historical, these statements are forward-looking in nature and express
the beliefs and expectations of management. Such statements are based on current
expectations and involve a number of known and unknown risks and uncertainties
that could cause IMPAX's future results, performance or achievements to differ
significantly from the results, performance or achievements expressed or implied
by such forward-looking statements. Such risks and uncertainties include, but
are not limited to, IMPAX's ability to obtain sufficient capital to fund its
operations, the difficulty of predicting FDA filings and approvals, consumer
acceptance and demand for new pharmaceutical products, the impact of competitive
products and pricing, IMPAX's ability to successfully develop and commercialize
pharmaceutical products, IMPAX's reliance on key strategic alliances, the
uncertainty of patent litigation, the availability of raw materials, the
regulatory environment, dependence on patent and other protection for innovative
products, exposure to product liability claims, fluctuations in operating
results and other risks detailed from time to time in IMPAX's filings with the
Securities and Exchange Commission. Forward-looking statements speak only as to
the date on which they are made, and IMPAX undertakes no obligation to update
publicly or revise any forward-looking statement, regardless of whether new
information becomes available, future developments occur or otherwise.

                                      # # #


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
